Rapid detection of minimal residual disease in acute myeloid leukemia from peripheral blood
Ended Cooperative Agreement Awarded Last action
- Award ID
- R44CA213595
- Recipient
-
Biofluidica, Inc. UEI LFTNJ5WJS5V8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,510,296
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date
- Originally
- Place of performance
- Chapel Hill, NC 27599, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $2,000 | |
| Amendment | $71,007 | |
| Amendment | $639,064 | |
| Original award | $798,225 |
Quick answers
Who received award R44CA213595?
R44CA213595 was awarded to Biofluidica, Inc. by National Cancer Institute (National Institutes of Health) on March 1, 2017.
How much is award R44CA213595 worth?
$1,510,296 has been obligated on R44CA213595.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award